Skip to main content
Figure 5 | Respiratory Research

Figure 5

From: Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

Figure 5

Mean changes from baseline in FEV 1 0–3 hours (A) on day 1 and (B) at week 24. Analyses were based on a mixed-model for repeated measures. *p< 0.05 versus placebo; †p< 0.05 versus aclidinium and placebo; §p< 0.05 versus aclidinium, formoterol, and placebo; ¥p< 0.05 versus aclidinium/formoterol FDC 400/6 and placebo. No significant differences between the two FDCs at any timepoint. ACL400/FOR12 FDC, fixed-dose combination of aclidinium 400μg and formoterol 12μg; ACL400/FOR6 FDC, fixed-dose combination of aclidinium 400μg and formoterol 6μg; FEV1, forced expiratory volume in 1 second; LS, least squares.

Back to article page